Literature DB >> 16838317

Clinical trials in children with Down syndrome: issues from a cognitive research perspective.

James H Heller1, Gail A Spiridigliozzi, Blythe G Crissman, Jennifer A Sullivan-Saarela, Jennifer S Li, Priya S Kishnani.   

Abstract

Clinical and translational research play a key role in the transition of basic research discoveries to effective therapies. In Down syndrome (DS), these research approaches are not well utilized or developed to test new therapies to improve cognitive and/or adaptive function in this population. This article reviews the history of clinical trial research in children with DS from a cognitive research perspective and discusses important issues relevant to the conduct of well designed clinical trials for this population. Specific issues addressed include: funding, study design, study medication, subject recruitment and retention, safety, and efficacy challenges. The Duke Down Syndrome Research Team's program of clinical research of cholinesterase inhibitors for individuals with DS serves as the model application for the identified research principles. It is hoped that this article will raise awareness of the unmet need for clinical research in the cognitive and adaptive function of individuals with DS, especially children with DS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16838317     DOI: 10.1002/ajmg.c.30103

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  8 in total

1.  Making the invisible visible: professional education to eliminate disparities in clinical trials.

Authors:  Larry Laufman
Journal:  J Cancer Educ       Date:  2009       Impact factor: 2.037

2.  Parental Perspectives on Pharmacological Clinical Trials: a Qualitative Study in Down Syndrome and Fragile X Syndrome.

Authors:  Victoria Reines; Krista Charen; Tracie Rosser; Arri Eisen; Stephanie L Sherman; Jeannie Visootsak
Journal:  J Genet Couns       Date:  2017-05-24       Impact factor: 2.537

3.  The Arizona Cognitive Test Battery for Down Syndrome: Test-Retest Reliability and Practice Effects.

Authors:  Jamie O Edgin; Payal Anand; Tracie Rosser; Elizabeth I Pierpont; Carlos Figueroa; Debra Hamilton; Lillie Huddleston; Gina Mason; Goffredina Spanò; Lisa Toole; Mina Nguyen-Driver; George Capone; Leonard Abbeduto; Cheryl Maslen; Roger H Reeves; Stephanie Sherman
Journal:  Am J Intellect Dev Disabil       Date:  2017-05

4.  Short-term memory outcome measures: Psychometric evaluation and performance in youth with Down syndrome.

Authors:  Emily K Schworer; Kellie Voth; Emily K Hoffman; Anna J Esbensen
Journal:  Res Dev Disabil       Date:  2021-12-15

5.  Evaluating Verbal Fluency Outcome Measures in Children With Down Syndrome.

Authors:  Catelyn N Smeyne; Anna J Esbensen; Emily K Schworer; Shequanna Belizaire; Emily K Hoffman; Dean W Beebe; Susan Wiley
Journal:  Am J Intellect Dev Disabil       Date:  2022-07-01

6.  Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.

Authors:  Adviye A Tolun; Peter M Scarbrough; Haoyue Zhang; Jane-Ann McKillop; Frances Wang; Priya S Kishnani; David S Millington; Sarah P Young; Dora Il'yasova
Journal:  Ann Epidemiol       Date:  2012-10-11       Impact factor: 3.797

7.  Assessment of Cognitive Scales to Examine Memory, Executive Function and Language in Individuals with Down Syndrome: Implications of a 6-month Observational Study.

Authors:  Xavier Liogier d'Ardhuy; Jamie O Edgin; Charles Bouis; Susana de Sola; Celia Goeldner; Priya Kishnani; Jana Nöldeke; Sydney Rice; Silvia Sacco; Lisa Squassante; Gail Spiridigliozzi; Jeannie Visootsak; James Heller; Omar Khwaja
Journal:  Front Behav Neurosci       Date:  2015-11-18       Impact factor: 3.558

Review 8.  Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group.

Authors:  Nicole T Baumer; Mara L Becker; George T Capone; Kathleen Egan; Juan Fortea; Benjamin L Handen; Elizabeth Head; James E Hendrix; Ruth Y Litovsky; Andre Strydom; Ignacio E Tapia; Michael S Rafii
Journal:  J Neurodev Disord       Date:  2022-03-23       Impact factor: 4.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.